A strategic focus on cardiovascular technology
Our focus is on products and technologies that will improve management of cardiovascular disease
Over the past decade, Hydrix has been at the forefront of developing critical technology for clients who are building total artificial hearts and heart pump devices.
Cardiovascular disease (CVD) is the world's leading cause of death. It afflicts 14% of the global population. As such, the devices market is expected to grow to US$70B by 2027. This represents a large & growing market opportunity for Hydrix.
We are therefore building on 20 years of experience in medtech product development to translate this knowhow into establishing Hydrix as a leading cardiovascular technology company.
Ambulatory Monitoring Devices
$3.8 B
$6.7 B
Interventional
Devices
$17.5 B
$26.8 B
Cardiac Rhythm
Management
$20.4 B
$31.2 B
Cardiovascular Surgery Devices
$1.9 B
$2.1 B
Our cardiovascular mission
In our pursuit of growing our cardiovascular market share, we are focusing on building out our capabilities and reputation, our market insights, growing and maturing key aspects of our business
Our people
We are constantly seeking to improve our cardiovascular credentials through engaging with researchers and technologists, industry professionals and key opinion leaders in Europe, USA, Asia and Australia. In addition to our design and engineering expertise, our team members seek real-world experience, attending operating theatres, facilitating clinical trials, and exploring and implementing go to market strategies.
Our team seeks to be across the latest market trends and technology advances to ensure Hydrix remains at the forefront of CVD technology design and distribution
Product development leadership
We continue to expand our market reach and capability in CVD device development. Currently, Hydrix is recognised as the company of choice for developing control systems for Mechanical Circulatory Support devices (MCS) including Total Artificial Hearts (TAH) and Ventricular Assist Devices (VAD), for medical companies in the US, EU and Australia.
Hydrix was also recently recognised with an International Good Design Award for our unique LUDO system, a platform technology that de-risks and accelerates client MCS programs, providing them with greater confidence in reaching their desired outcome.
Learn more about LUDO
Growing our product sales and distribution business
Our objective is to have three or more cardiovascular technology products in the market by 2025, producing $50m of annual product revenues, and driving the Company’s growth prospects. In realising this objective, we have negotiated two cardiac products exclusive distribution deals.
Both products are unique in how they solve unmet market needs. In particular, the FDA-approved AngelMed GUARDIAN® is the world's only patient implantable heart attack alert system. We expect initial commercial sales of the GUARDIAN in Australia in CY2022 as regulatory approvals are granted.
We continue to explore opportunities to acquire and develop additional MedTech products, enabling us to expand beyond 3rd party distribution arrangements. We therefore are regularly engaging in discussions with potential product partners.
Learn more about Hydrix Medical